Research Analysts Issue Forecasts for FBIO Q1 Earnings

Fortress Biotech, Inc. (NASDAQ:FBIO) – Roth Capital lowered their Q1 2025 earnings estimates for shares of Fortress Biotech in a research note issued on Wednesday, April 2nd. Roth Capital analyst J. Wittes now anticipates that the biopharmaceutical company will post earnings of ($0.44) per share for the quarter, down from their prior forecast of $1.47. The consensus estimate for Fortress Biotech’s current full-year earnings is ($3.28) per share. Roth Capital also issued estimates for Fortress Biotech’s Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.64) EPS and FY2026 earnings at ($0.94) EPS.

Separately, Roth Mkm reaffirmed a “buy” rating and issued a $16.00 target price (up from $15.00) on shares of Fortress Biotech in a research note on Tuesday, March 11th.

Fortress Biotech Stock Performance

Shares of FBIO opened at $1.52 on Monday. The stock has a 50-day moving average price of $1.68 and a 200-day moving average price of $1.77. The company has a market cap of $41.96 million, a PE ratio of -0.50 and a beta of 1.75. Fortress Biotech has a 12-month low of $1.36 and a 12-month high of $2.89.

Fortress Biotech (NASDAQ:FBIO) last posted its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.53. The business had revenue of $15.12 million for the quarter, compared to the consensus estimate of $16.30 million.

Institutional Investors Weigh In On Fortress Biotech

Large investors have recently added to or reduced their stakes in the company. Wolverine Trading LLC purchased a new position in shares of Fortress Biotech in the 4th quarter worth about $26,000. Weaver Consulting Group lifted its position in Fortress Biotech by 33.0% in the 4th quarter. Weaver Consulting Group now owns 22,998 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 5,700 shares during the last quarter. XTX Topco Ltd purchased a new stake in Fortress Biotech in the fourth quarter worth approximately $62,000. Jane Street Group LLC bought a new position in Fortress Biotech during the fourth quarter valued at approximately $69,000. Finally, PFG Investments LLC raised its stake in shares of Fortress Biotech by 82.8% during the fourth quarter. PFG Investments LLC now owns 35,259 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 15,968 shares in the last quarter. Hedge funds and other institutional investors own 96.51% of the company’s stock.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.